If approved, etrasimod will mount a direct challenge to Bristol-Myers Squibb's S1P drug Zeposia (ozanimod), which was approved for UC last year and also for a green light to treat multiple ...

but will be watched keenly to see how it stacks up with etrasimod's main rival, Bristol-Myers Squibb's S1P drug Zeposia (ozanimod), which was approved for ulcerative colitis last year and is also ...

Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment; Etrasimod demonstrates robust efficacy across multiple endpoin ...